Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

AIMOVIG Solution for injection (2020)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Aimovig 70 mg solution for injection in pre-filled syringe. Aimovig 140 mg solution for injection in pre-filled syringe. Aimovig 70 mg solution for injection in pre-filled pen. Aimovig 140 mg solution ...

Qualitative and quantitative composition

Aimovig 70 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 70 mg erenumab. Aimovig 140 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains ...

Pharmaceutical form

Solution for injection (injection). The solution is clear to opalescent, colourless to light yellow.

Therapeutic indications

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Posology and method of administration

Treatment should be initiated by physicians experienced in the diagnosis and treatment of migraine. Posology Treatment is intended for patients with at least 4 migraine days per month when initiating treatment ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Patients with certain major cardiovascular diseases were excluded from clinical studies (see section 5.1). No safety data are available in these patients. Hypersensitivity reactions Serious hypersensitivity ...

Interaction with other medicinal products and other forms of interaction

No effect on exposure of co-administered medicinal products is expected based on the metabolic pathways of monoclonal antibodies. No interaction with oral contraceptives (ethinyl estradiol/norgestimate) ...

Pregnancy and lactation

Pregnancy There are a limited amount of data from the use of erenumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section ...

Effects on ability to drive and use machines

Aimovig is expected to have no or negligible influence on the ability to drive and use machines.

Undesirable effects

Summary of the safety profile A total of over 2,500 patients (more than 2,600 patient years) have been treated with Aimovig in registration studies. Of these, more than 1,300 patients were exposed for ...

Overdose

No cases of overdose have been reported in clinical studies. Doses up to 280 mg have been administered subcutaneously in clinical studies with no evidence of dose-limiting toxicity. In the event of an ...

Pharmacodynamic properties

Pharmacotherapeutic group: Analgesics, antimigraine preparations ATC code: N02CX07 Mechanism of action Erenumab is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor. ...

Pharmacokinetic properties

Erenumab exhibits non-linear kinetics as a result of binding to the CGRP-R receptor. However, at therapeutically relevant doses, the pharmacokinetics of erenumab following subcutaneous dosing every 4 weeks ...

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, toxicity to reproduction and development. Carcinogenicity studies have ...

List of excipients

Sucrose Polysorbate 80 Sodium hydroxide (for pH adjustment) Glacial acetic acid Water for injections

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Shelf life

Shelf life: 2 years.

Special precautions for storage

Pre-filled syringe: Store in a refrigerator (2°C-8°C). Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light. After removal from the refrigerator, Aimovig must be ...

Nature and contents of container

Pre-filled syringe: Aimovig is supplied in a pre-filled syringe (1 ml, Type 1 glass) with a stainless steel needle and a needle cover (rubber containing latex). Aimovig is available in packs containing ...

Special precautions for disposal and other handling

Before administration, the solution should be inspected visually. The solution should not be injected if it is cloudy, distinctly yellow or contains flakes or particles. Pre-filled syringe: To avoid discomfort ...

Marketing authorization holder

Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Marketing authorization number(s)

EU/1/18/1293/001-006

Date of first authorization / renewal of the authorization

26 July 2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: